Worth reading
—
Scored from 0 of 6 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
880
Hundreds of millions of yenWording
Conditional
How definitive the wording is.Results for this period
Full year1 April 2025–31 March 2026Net Sales880Hundreds of millions of yen
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Regional sales446 Hundreds of millions of yen, 244 Hundreds of millions of yen, 124 Hundreds of millions of yen
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | 880 Hundreds of millions of yen |
| Regional sales | 446 Hundreds of millions of yen, 244 Hundreds of millions of yen, 124 Hundreds of millions of yen |
Items this document does not state (34)
Accounting standardsConsolidated / non-consolidatedOperating profitOrdinary incomeProfit attributable to owners of the parentNet income per shareOperating MarginEquity ratioTotal assetsNet assetsCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastAnnual Dividend ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitOrders received and order backlogDepreciation and amortizationImpairment lossBreakdown of extraordinary income (loss)Disclosure regarding the going concern assumptionChange in accounting policyChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-EndFactors Behind Changes in Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The disclosure was made in conjunction with Biogen Inc.'s announcement of its first-quarter 2026 results on 29 April 2026. Details of the company's fiscal 2025 results are scheduled to be disclosed in its earnings announcement on 15 May 2026. No reasons for the increase or decrease in revenue were provided.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.